Qx Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Qx Therapeutics is a private, pre-revenue biotech targeting high-mortality lung injuries like ALI and ARDS with its novel MAP3K2/3 inhibition platform. The company's lead asset, QXT-101, has secured FDA Fast Track designation and is in Phase 2 development for Pulmonary Graft Dysfunction (PGD) following lung transplantation, with prior authorization for a trial in severe COVID-19. With a focused pipeline and a mechanism applicable to a wide range of lung insults, Qx aims to address a significant unmet medical need in critical care.

Acute Lung InjuryAcute Respiratory Distress SyndromePulmonary Graft Dysfunction

Technology Platform

Novel small molecule inhibitors targeting MAP3K2 and MAP3K3 kinases to treat the underlying inflammatory and cell death pathways in lung injury.

Opportunities

The significant unmet need in ALI/ARDS, with no approved pharmacologic therapies, presents a major market opportunity.

The FDA Fast Track designation for PGD can accelerate development and review, and the platform's potential applicability to various causes of lung injury could allow expansion into multiple indications.

Risk Factors

High clinical risk as the novel MAP3K2/3 mechanism is unproven in late-stage trials.

As a single-asset, private company, it faces binary clinical outcomes and ongoing financing needs.

Competition from other entities developing ARDS therapies poses a market threat.

Competitive Landscape

The ARDS therapeutic landscape is crowded with investigational agents but lacks any approved drugs, leaving the standard of care as supportive. Qx competes with other biotechs and academic groups exploring anti-inflammatory, anti-fibrotic, and endothelial barrier-protecting approaches. Its differentiation lies in its first-in-class MAP3K2/3 inhibition mechanism.

More companies in United States →